Hjem › Metastatisk kreft › Virginia › Richmond
Kliniske studier for Metastatisk kreft i Richmond, VA
12 studier for Metastatisk kreft søker deltakere på steder i og rundt Richmond (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruttererFase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RekruttererFase 3
- Virginia Cancer Institute, Richmond
- Virginia Cancer Institute, Richmond
- Virginia Cancer Institute, Mechanicsville · 6 mi unna
- og 2 flere
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekruttererFase 3
- Research Site, Midlothian · 11 mi unna
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
RekruttererFase 3
- Research Site, Midlothian · 11 mi unna
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RekruttererFase 3
- VCU Health Adult Outpatient Pavillion, Richmond
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
RekruttererFase 2
- VCU Massey Comprehensive Cancer Center, Richmond
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekruttererFase 2
- Virginia Commonwealth University Massey Cancer Center, Richmond
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RekruttererFase 3
- Research Site, Richmond
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
RekruttererFase 3
- Bon Secours St. Francis Medical Oncology Center, Midlothian · 11 mi unna
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
RekruttererFase 2/3
- Virginia Commonwealth University, Richmond
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekruttererFase 3
- VCU Massey Cancer Center, Richmond
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RekruttererFase 2/3
- Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond
Metastatisk kreft-studier i andre byer
- Houston, TX104 studier
- New York City, NY93 studier
- Nashville, TN70 studier
- Boston, MA63 studier
- Los Angeles, CA57 studier
- St. Louis, MO54 studier
- Arlington, VA53 studier
- Philadelphia, PA46 studier
- Chicago, IL45 studier
- San Antonio, TX44 studier
- Washington, DC43 studier
- Dallas, TX42 studier
Andre studier i Richmond
- Brystkreft26 studier
- Ikke-småcellet lungekreft25 studier
- Prostatakreft19 studier
- Hjertesvikt16 studier
- Lungekreft14 studier
- Kardiovaskulær sykdom13 studier
- Kolorektal kreft13 studier
- Steatotisk leversykdom12 studier
- Akut myelogen leukemi12 studier
- Plateepitelcancer i hode og hals12 studier
- Melanom11 studier
- Fedme11 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.